Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been demonstrated to play a critical role in regulating cholesterol homeostasis and T cell antitumor immunity. However, the expression, function, and therapeutic value of PCSK9 in head and neck squamous cell carcinoma (HNSCC) remain largely unexplored. Here, we found that the expression of PCSK9 was upregulated in HNSCC tissues, and higher PCSK9 expression indicated poorer prognosis in HNSCC patients. We further found that pharmacological inhibition or siRNA downregulating PCSK9 expression suppressed the stemness-like phenotype of cancer cells in an LDLR-dependent manner. Moreover, PCSK9 inhibition enhanced the infiltration of CD8+ T cells and reduced the myeloid-derived suppressor cells (MDSCs) in a 4MOSC1 syngeneic tumor-bearing mouse model, and it also enhanced the antitumor effect of anti-PD-1 immune checkpoint blockade (ICB) therapy. Together, these results indicated that PCSK9, a traditional hypercholesterolemia target, may be a novel biomarker and therapeutic target to enhance ICB therapy in HNSCC.
Pubmed ID: 37305703 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
Mus musculus with name C57BL/6J from IMSR.
View all literature mentionsThis monoclonal targets Human CD44
View all literature mentionsThis isotype control targets not applicable
View all literature mentionsThis recombinant monoclonal targets CD8
View all literature mentionsThis monoclonal targets FOXP3
View all literature mentionsThis monoclonal targets ALDH1A1
View all literature mentionsThis monoclonal targets SOX2
View all literature mentionsThis recombinant monoclonal targets Granzyme B
View all literature mentionsThis monoclonal targets IFN-gamma
View all literature mentionsThis monoclonal targets TNF-alpha
View all literature mentionsThis monoclonal targets Ly-6G
View all literature mentionsThis monoclonal targets Ly-6C
View all literature mentionsThis monoclonal targets MHC Class II (I-A/I-E)
View all literature mentionsThis monoclonal targets CD11b
View all literature mentionsThis monoclonal targets CD279
View all literature mentionsThis monoclonal targets CD366
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD4
View all literature mentionsThis monoclonal targets CD3
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets CD45
View all literature mentionsThis monoclonal targets GAPDH
View all literature mentionsThis monoclonal targets Beta Actin
View all literature mentionsThis monoclonal targets Ki-67
View all literature mentionsThis monoclonal targets GZMB
View all literature mentionsThis monoclonal targets ARG1
View all literature mentionsThis monoclonal targets CD8a
View all literature mentionsThis monoclonal targets CD133
View all literature mentionsThis polyclonal targets SREBF2
View all literature mentionsThis polyclonal targets HMGCR
View all literature mentionsThis polyclonal targets PCSK9
View all literature mentions